Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis

Purpose: Sorafenib and sunitinib are extensively used as first-line medications for metastatic renal cell carcinoma (mRCC). This meta-analysis was conducted to assess the antitumor efficacy, toxicity, and costs of the two drugs among mRCC patients.Materials and methods: PubMed, ScienceDirect, Scopus...

Full description

Bibliographic Details
Main Authors: Huan Deng, Wenfeng Liu, Ting He, Zhengdong Hong, Fengming Yi, Yiping Wei, Wenxiong Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-06-01
Series:Frontiers in Oncology
Subjects:
sorafenib
sunitinib
targeted therapy
renal cell carcinoma
meta-analysis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00479/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00479/full

Similar Items